Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Taro Pharmaceutical Industries stock

TARO
IL0010827181
897505

Price

42.97
Today +/-
+0
Today %
+0 %

Taro Pharmaceutical Industries stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Taro Pharmaceutical Industries stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Taro Pharmaceutical Industries stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Taro Pharmaceutical Industries stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Taro Pharmaceutical Industries's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Taro Pharmaceutical Industries Stock Price History

DateTaro Pharmaceutical Industries Price
6/21/202442.97 undefined
6/20/202442.97 undefined

Taro Pharmaceutical Industries Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Taro Pharmaceutical Industries, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Taro Pharmaceutical Industries from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Taro Pharmaceutical Industries’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Taro Pharmaceutical Industries. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Taro Pharmaceutical Industries’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Taro Pharmaceutical Industries’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Taro Pharmaceutical Industries’s growth potential.

Taro Pharmaceutical Industries Revenue, EBIT and net profit per share

DateTaro Pharmaceutical Industries RevenueTaro Pharmaceutical Industries EBITTaro Pharmaceutical Industries Net Income
2025e690 M undefined98.2 M undefined107.01 M undefined
2024629.18 M undefined21.51 M undefined53.87 M undefined
2023573 M undefined17.7 M undefined25.4 M undefined
2022561.3 M undefined125 M undefined58.3 M undefined
2021549 M undefined145.1 M undefined-386.7 M undefined
2020644.8 M undefined246.5 M undefined244.2 M undefined
2019669.9 M undefined292.5 M undefined281.8 M undefined
2018661.9 M undefined304.9 M undefined211.2 M undefined
2017879.4 M undefined515.3 M undefined456.4 M undefined
2016950.8 M undefined617.5 M undefined540.9 M undefined
2015862.9 M undefined523.4 M undefined484.3 M undefined
2014759.3 M undefined432.9 M undefined360.4 M undefined
2013671 M undefined361.9 M undefined266.2 M undefined
2012145.1 M undefined66.2 M undefined47.3 M undefined
2011505.7 M undefined204.7 M undefined182.7 M undefined
2010392.5 M undefined89.2 M undefined64.1 M undefined
2009355.9 M undefined75.3 M undefined114 M undefined
2008327.4 M undefined57 M undefined30.5 M undefined
2007318.5 M undefined67.9 M undefined34.3 M undefined
2006252.3 M undefined-16.6 M undefined-82.7 M undefined
2005288.6 M undefined9.5 M undefined100,000 undefined

Taro Pharmaceutical Industries Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e
891112202628424956616683103149211278271288252318327355392505145671759862950879661669644549561573629690
-12.5022.229.0966.6730.007.6950.0016.6714.298.938.2025.7624.1044.6641.6131.75-2.526.27-12.5026.192.838.5610.4228.83-71.29362.7613.1113.5710.21-7.47-24.801.21-3.74-14.752.192.149.779.70
37.5033.3336.3650.0050.0050.0053.5759.5257.1455.3650.8254.5557.8360.1963.0962.5662.9552.7757.6450.7959.7557.1958.8759.4465.1568.2873.6276.4278.4282.2176.3470.0566.5261.9653.9252.2346.7748.3344.06
33461013152528313136486294132175143166128190187209233329994945806767816714634453992962932683040
000010032212510264430-370-8234301146418247266360484540456211281244-386582553107
---------33.33--50.00100.00150.00100.00160.0069.23-31.82-223.33---141.46-11.76280.00-43.86184.38-74.18465.9635.3434.4411.57-15.56-53.7333.18-13.17-258.20-115.03-56.90112.00101.89
11.811.811.811.814.118.318.519.720.920.820.820.221.523.926.329.429.729.129.629.335.240.440.641.944.544.644.744.342.842.841.340.23938.538.237.637.637.580
---------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Taro Pharmaceutical Industries Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Taro Pharmaceutical Industries is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (B)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
1988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                                         
0000000000000.010.150.130.160.10.070.020.050.080.110.090.240.320.550.630.921.231.391.421.051.111.020.820.850.88
2.62.64.15.97.69.113.312.9161820.325.238.741.169120.548.735.639.57062.161.673.4120.8111.1119.8138.8222.4238.6203.9206.5237.9235.2213.5247202.3177.46
00000000.60.71.20.81.11.84.37.87.76.253.417.39.55.86.94.653.622.94348.7125.4116.740.32940.546.545.441.77
22.32.53.75.75.88.711.213.114.814.718.219.629.142.484.586.660.356.86766.16883.7107.4109.6109.6117.6120.3138.6141144.6148.1153.1180.3210.4226.7204.82
00001.71.51.62.42.62.72.83.24.46.37.211.914.623.717.6910.139.842.8105.9109.4123.6139.8208.1223.1141.96.37.16.612.913.211.70
00.010.010.010.020.020.020.030.030.040.040.050.070.230.260.380.250.20.130.210.230.290.30.580.650.911.051.511.8821.91.481.531.471.341.341.3
2.42.52.13.69.411.11316.223.728.729.634.641.85493.4182.3242246.3219.8211.9186.5176.2163.6152.5150.8145.3151.4153159.5180.1193.7206.2212.2208.2205.1194217.59
0.10.700000000001.12.81.32.9000000000000115.270.7225.6304.3459.6557.2435.2404.9457.99
000000000000000020.235.131.526.627.931.530.723.12023.252.946.3000000000
00000000.10.10.1001.12.47.329.462.25929.126.423.820.922.719.118.315.616.613.28.35.97.18.98.46.847.363.60
0.80.7000004.64.54.44.34.243.87.27.27.27.27.27.37.27.37.37.37.37.37.27.27.27.27.27.27.27.211.817.217.23
000.711.154.90.6110.91.40.713.213.611.11.23.13.72.81.150.536.612.36.55.54.94.220.326.8102.9126121.3156.6139119.4165.85
3.33.92.84.610.516.117.921.529.334.234.840.248.776.2122.8232.9332.8350.7291.3275246.5286.4260.9214.3202.9196.9233223.9310.5290.7536.5652.6808.7936838.4799.1858.67
0.010.010.010.010.030.030.040.050.060.070.070.090.120.310.380.620.590.550.420.480.470.580.560.80.861.111.281.742.192.292.432.142.342.412.182.142.16
                                                                         
7007007007007007007007007007007007007007007007007007007007007007007007007007007007007007007007007007007007000
1.81.81.84.38.516.117.217.217.317.417.422.824167.6173.6182.7162163.9165.1221.8222.1222.6244.7253.6253.6261262.4262.4262.4262.4262.4262.4262.4262.4262.4262.40
-0-0-000000.010.010.010.010.020.030.050.10.160.06-0.05-0.13-0.1-0.070.050.110.30.340.610.971.451.992.452.662.482.732.342.392.410
-00-0-0-0-0-0-0-0-0-0-0-0-0-00.010.010.010.010.030.010.020.020.020.020.02-0.02-0.11-0.12-0.15-0.11-0.14-0.16-0.15-0.17-0.181.79
0000000000000000000000000000000000000
00000.010.020.020.020.030.030.030.040.050.220.270.350.230.130.050.150.170.290.380.570.620.891.211.612.132.572.822.62.832.452.482.51.79
1.82.13.33.95.55.67.64.64.87.95.55.48.912.725.226.117.824.123.520.325.941.434.655.656.446.653.362.766.953.362.367667887.690.944.66
00000003.95.54.74.56.59.912.420.231.157.411.913.620.818.218.425.325.523.324.829.535.336.433.237.137.437.342.451.2490
000000.510.10.90.81.31.50.81.52.636.6105.378.651.465.445.341.692.2108.3109.8158.6211.1142.1123.4116.3112.4119.4555.9293.3245.7316.44
11.92.12.54.45.79.94.37.911.113.66.22.22.22.319.16596.5119.3109100.196.114.900000000000000
0.10.20.20.51.11.70.50.71.12.52.95.26.36824.416.912.528.431.329.929.313.317.11111.3120.9000000000
2.94.25.66.91113.51913.620.22727.824.828.134.858.3103.7163.7250.3263.4232.8239.5230.5129.7190.4199192.5253.4310245.4209.9215.7216.8222.7676.3432.1385.6361.11
2.72.72.52.53.72.51.811.414.716.116.323.338.349.347.1156.9184.4152.890.476.45838.431.227.627.917.35.95000000000
00000000.40.50.50.91.32.53.42.84.956.45.55.63.83.82.31.92.21.91.71.92.22.13.233.41.9007.96
0.70.80.80.60.80.20.30.10.60.60.60.91.21.11.41.94.110.515.415.37.77.68.64.94.442.93.53.243.84.45.433.232.819.10
3.43.53.33.14.52.72.111.915.817.217.825.54253.851.3163.7193.5169.7111.397.369.549.842.134.434.523.210.510.45.46.177.48.835.132.819.17.96
6.37.78.91015.516.221.125.53644.245.650.370.188.6109.6267.4357.2420374.7330.1309280.3171.8224.8233.5215.7263.9320.4250.8216222.7224.2231.5711.4464.9404.7369.06
0.010.010.010.010.030.030.040.050.060.070.070.090.120.310.380.620.590.550.430.480.470.570.550.790.851.11.471.932.392.783.042.823.063.162.952.912.16
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Taro Pharmaceutical Industries provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Taro Pharmaceutical Industries's financial health and stability.

Assets

Taro Pharmaceutical Industries's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Taro Pharmaceutical Industries must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Taro Pharmaceutical Industries after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Taro Pharmaceutical Industries's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
00010032212510264430-370-8234301166418347266360484541456210282244-4005825
00000111234456814202425222118181841716151414161821232532
00000000000002-1100-320-786-214-18-23-70-127356127-382316
-100-2-20-4-3-3-1-3-6-10-6-27-4111-9-20-6116-3-24022-1810-9-137-8073710460-279-53
0000000000000050035737104001-6-13-11-2733-26-1201210
000000112233332378131412863021100000000
000000120001213504333129511331171011939755130335-10
-100000001223627295-517-2417463701817824835740639543732332327145-15831
-100-2-6-2-3-4-8-9-6-8-12-19-43-104-91-49-22-6-4-5-10-6-1-10-25-20-19-35-29-30-28-17-111-19
000-2-8-4-3-4-8-9-5-8-13-20-49-104-123-36-14-20-13-24-8015-243-173-92-284-117-241257-29867-170-125
1000-1-2000000-1-1-60-31132010-16-8-13-7417-233-147-71-265-82-212287-26984-59-105
000000000000000000000000000000000000
00004123763711901256610-28-32-29-28-107-12-6-10-11-10-50000000
000244100000012702110560021806-1910-9-294-107-88-27-24-240
000385337636111370127546-3023-28-28-86-4-6-3-203-10-15-294-107-588-27-24-240
-----------------14.00-5.00-2.00-----------------
0000000000000000000000000000000-5000000
0000010000014143-2028-73-12-56292324-3995880-272719523-23-9-5491-354-96
-2.2-0.2-0.5-2.5-7.1-2.6-3.1-4-7.6-6.2-3.4-4.5-5.98.1-13.6-99.5-97-32.4-47-570.758.859.7175.176.5238.5331.8386.6376401.7294.2293243.228.6-27012
000000000000000000000000000000000000

Taro Pharmaceutical Industries stock margins

The Taro Pharmaceutical Industries margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Taro Pharmaceutical Industries. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Taro Pharmaceutical Industries.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Taro Pharmaceutical Industries's sales revenue. A higher gross margin percentage indicates that the Taro Pharmaceutical Industries retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Taro Pharmaceutical Industries's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Taro Pharmaceutical Industries's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Taro Pharmaceutical Industries's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Taro Pharmaceutical Industries. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Taro Pharmaceutical Industries's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Taro Pharmaceutical Industries Margin History

Taro Pharmaceutical Industries Gross marginTaro Pharmaceutical Industries Profit marginTaro Pharmaceutical Industries EBIT marginTaro Pharmaceutical Industries Profit margin
2025e48.47 %14.23 %15.51 %
202448.47 %3.42 %8.56 %
202346.82 %3.09 %4.43 %
202252.22 %22.27 %10.39 %
202154.04 %26.43 %-70.44 %
202061.99 %38.23 %37.87 %
201966.53 %43.66 %42.07 %
201870.03 %46.06 %31.91 %
201776.36 %58.6 %51.9 %
201682.14 %64.95 %56.89 %
201578.41 %60.66 %56.12 %
201476.39 %57.01 %47.46 %
201373.74 %53.93 %39.67 %
201268.37 %45.62 %32.6 %
201165.16 %40.48 %36.13 %
201059.49 %22.73 %16.33 %
200958.72 %21.16 %32.03 %
200857.39 %17.41 %9.32 %
200759.78 %21.32 %10.77 %
200651.05 %-6.58 %-32.78 %
200557.52 %3.29 %0.03 %

Taro Pharmaceutical Industries Stock Sales Revenue, EBIT, Earnings per Share

The Taro Pharmaceutical Industries earnings per share therefore indicates how much revenue Taro Pharmaceutical Industries has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Taro Pharmaceutical Industries earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Taro Pharmaceutical Industries's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Taro Pharmaceutical Industries’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Taro Pharmaceutical Industries's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Taro Pharmaceutical Industries Revenue, EBIT and net profit per share

DateTaro Pharmaceutical Industries Sales per ShareTaro Pharmaceutical Industries EBIT per shareTaro Pharmaceutical Industries Earnings per Share
2025e18.36 undefined0 undefined2.85 undefined
202416.74 undefined0.57 undefined1.43 undefined
202315.24 undefined0.47 undefined0.68 undefined
202214.93 undefined3.32 undefined1.55 undefined
202114.37 undefined3.8 undefined-10.12 undefined
202016.75 undefined6.4 undefined6.34 undefined
201917.18 undefined7.5 undefined7.23 undefined
201816.47 undefined7.58 undefined5.25 undefined
201721.29 undefined12.48 undefined11.05 undefined
201622.21 undefined14.43 undefined12.64 undefined
201520.16 undefined12.23 undefined11.32 undefined
201417.14 undefined9.77 undefined8.14 undefined
201315.01 undefined8.1 undefined5.96 undefined
20123.25 undefined1.48 undefined1.06 undefined
201111.36 undefined4.6 undefined4.11 undefined
20109.37 undefined2.13 undefined1.53 undefined
20098.77 undefined1.85 undefined2.81 undefined
20088.1 undefined1.41 undefined0.75 undefined
20079.05 undefined1.93 undefined0.97 undefined
20068.61 undefined-0.57 undefined-2.82 undefined
20059.75 undefined0.32 undefined0 undefined

Taro Pharmaceutical Industries business model

Taro Pharmaceutical Industries Ltd. is a company that focuses on generic and specialized pharmaceutical products. The company was founded in Israel in 1950 and has since relocated its headquarters to Ireland. Taro Pharmaceutical has become one of the largest providers of generics and specialty drugs over the years due to its extensive experience, high-quality products, and ability to adapt to changing market conditions. The business model of Taro Pharmaceutical Industries is extremely simple. They offer affordable generic medications. The company's focus is on developing, manufacturing, and distributing generic products on the global market. Taro also has a wide range of specialty drugs, including dermatological and ophthalmology products. Taro Pharmaceutical Industries Ltd.'s business activities are divided into two divisions: Farmaceutica Taro, which specializes in the development, manufacturing, and distribution of generics and specialty drugs, and Taro Research & Development Center, which focuses on researching and developing new medications and generic products. Taro Pharmaceutical Industries Ltd. offers a wide range of products, including tablets, ointments, and eye drops. The company provides a variety of products in various therapeutic areas such as dermatology, cardiology, urology, gynecology, neurology, pediatrics, gastroenterology, and infectious diseases. The dermatological products of Taro Pharmaceutical, such as Clobetasol Propionate Cream and Lidocaine, are known for their effectiveness in skincare. With its eye products like Dorzolamide and Timolol Maleate Ophthalmic Solution, the company focuses on the ophthalmology field. Taro also produces medications that help with cardiovascular diseases, such as Amlodipine and Enalapril. Taro Pharmaceutical Industries Ltd. was founded in 1950 by chemist George Rosenberg and his partner Leo Ringer in Haifa, Israel. Manufacturing of pharmaceutical ingredients for drug production began in 1951. The company has been focused on growth since its inception and has built a strong reputation for its production quality. In 1969, Taro Pharmaceutical went public with a market capitalization of approximately 8 million US dollars. Over the years, the company expanded its portfolio and grew rapidly through acquisitions of other companies and expansion into international locations such as Canada, Switzerland, Mexico, Spain, and Italy. Taro Pharmaceutical was sold to Italian pharma company Ariston in 1993 and acquired by Indian pharma company Sun Pharmaceutical Industries in 2013. The company's headquarters is now in Dublin, Ireland, and it produces for markets worldwide, including North America, Europe, Asia, Australia, and South America. In conclusion, Taro Pharmaceutical Industries is one of the leading companies in the generic production field and has become a strong player in the specialized pharmaceutical products sector. The company has proven its expertise in research and development, manufacturing, and distribution of sought-after products. With the global demand for medications expected to continue rising, a company like Taro, which offers sustainable and affordable preventive solutions, plays an important role in the healthcare industry and will continue to do so in the future. Taro Pharmaceutical Industries is one of the most popular companies on Eulerpool.com.

Taro Pharmaceutical Industries SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Taro Pharmaceutical Industries Revenue by Segment

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Taro Pharmaceutical Industries Revenue by Segment

Segmente2022
Royalty-

Taro Pharmaceutical Industries Revenue by Region

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Taro Pharmaceutical Industries Revenue by Segment

DateCANADACanada and Cayman islandsISRAELOther CountryUnited States
2022130.07 M USD130.07 M USD47.92 M USD6.69 M USD376.68 M USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Taro Pharmaceutical Industries Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Taro Pharmaceutical Industries historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Taro Pharmaceutical Industries shares outstanding

The number of shares was Taro Pharmaceutical Industries in 2023 — This indicates how many shares 37.6 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Taro Pharmaceutical Industries earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Taro Pharmaceutical Industries's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Taro Pharmaceutical Industries’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Taro Pharmaceutical Industries's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Taro Pharmaceutical Industries stock splits

In Taro Pharmaceutical Industries's history, there have been no stock splits.

Taro Pharmaceutical Industries dividend history and estimates

In 2023, Taro Pharmaceutical Industries paid a dividend amounting to 0 USD. Dividend means that Taro Pharmaceutical Industries distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Taro Pharmaceutical Industries provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Taro Pharmaceutical Industries’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Taro Pharmaceutical Industries's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Taro Pharmaceutical Industries Dividend History

DateTaro Pharmaceutical Industries Dividend
2025e6.95 undefined
201812.86 undefined

Taro Pharmaceutical Industries dividend payout ratio

In 2023, Taro Pharmaceutical Industries had a payout ratio of 244.02%. The payout ratio indicates the percentage of the company's profits that Taro Pharmaceutical Industries distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Taro Pharmaceutical Industries represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Taro Pharmaceutical Industries could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Taro Pharmaceutical Industries's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Taro Pharmaceutical Industries Payout Ratio History

DateTaro Pharmaceutical Industries Payout ratio
2025e244.02 %
2024244.02 %
2023244.02 %
2022244.02 %
2021244.02 %
2020244.02 %
2019244.02 %
2018244.02 %
2017244.02 %
2016244.02 %
2015244.02 %
2014244.02 %
2013244.02 %
2012244.02 %
2011244.02 %
2010244.02 %
2009244.02 %
2008244.02 %
2007244.02 %
2006244.02 %
2005244.02 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Taro Pharmaceutical Industries.

Taro Pharmaceutical Industries latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/20240.32 0.4  (26.5 %)2024 Q4
12/31/20230.31 0.54  (76.47 %)2024 Q3
9/30/20230.18 0.38  (106.97 %)2024 Q2
6/30/20230.32 0.4  (26.5 %)2024 Q1
3/31/20230.23 0.18  (-23.27 %)2023 Q4
12/31/20220.89 0.19  (-78.59 %)2023 Q3
9/30/20220.86 -0.07  (-108.17 %)2023 Q2
6/30/20220.87 0.37  (-57.32 %)2023 Q1
3/31/20220.9 0.73  (-18.67 %)2022 Q4
12/31/20210.93 0.7  (-24.59 %)2022 Q3
1
2
3

Eulerpool ESG Scorecard© for the Taro Pharmaceutical Industries stock

Eulerpool World ESG Rating (EESG©)

33/ 100

🌱 Environment

4

👫 Social

67

🏛️ Governance

29

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Taro Pharmaceutical Industries shareholders

%
Name
Stocks
Change
Date
100.01232 % Sun Pharmaceutical Industries Ltd37,584,6318,086,8186/24/2024
1.72988 % Krensavage Asset Management, LLC650,0892,2216/30/2024
0.03608 % Analyst I.M.S., Investment Management Services Ltd.13,55706/30/2024
0.03359 % Rhumbline Advisers Ltd. Partnership12,6253,0186/30/2024
0.02145 % SELECTRA Management Company S.A.8,0612,3616/30/2023
0.01521 % Cetera Advisors LLC5,7165,7163/31/2024
0.01072 % SunAmerica Asset Management, LLC4,030-343/31/2024
0.01026 % Mercer Global Investments Management Ltd3,85504/30/2024
0.00636 % Florida State Board of Administration2,390-2,0806/30/2024
0.00532 % LRI Investments, LLC2,00006/30/2024
1
2
3
4
5
...
10

Most common questions regarding Taro Pharmaceutical Industries

What values and corporate philosophy does Taro Pharmaceutical Industries represent?

Taro Pharmaceutical Industries Ltd represents a commitment to delivering high-quality pharmaceutical products to patients worldwide. The company's corporate philosophy centers around innovation, quality, and customer satisfaction. Taro is dedicated to investing in research and development to bring innovative healthcare solutions to market. With a focus on excellence, Taro upholds strict quality standards throughout its manufacturing processes. The company strives to enhance patients' well-being by providing a diverse portfolio of affordable and accessible medications. Taro Pharmaceutical Industries Ltd prioritizes ethical practices, integrity, and transparency in its operations, ensuring trust and reliability in the pharmaceutical industry.

In which countries and regions is Taro Pharmaceutical Industries primarily present?

Taro Pharmaceutical Industries Ltd is primarily present in various countries and regions around the world. As a global pharmaceutical company, Taro operates in multiple markets, including the United States, Canada, Europe, Israel, and other countries. With its headquarters in Israel, Taro has established a strong presence in key pharmaceutical markets, offering a wide range of prescription and over-the-counter products. By consistently expanding its international operations and partnerships, Taro continues to serve patients in different regions and contribute to the advancement of healthcare globally.

What significant milestones has the company Taro Pharmaceutical Industries achieved?

Taro Pharmaceutical Industries Ltd has achieved several significant milestones in its history. The company has successfully developed and launched a wide range of generic pharmaceutical products, establishing a strong presence in various global markets. Taro has also demonstrated its commitment to quality and patient safety by achieving various regulatory approvals and certifications. Furthermore, the company has made significant strides in research and development, continuously innovating and introducing new therapies to improve patient outcomes. Taro Pharmaceutical Industries Ltd has consistently shown its dedication to the healthcare industry, making it a notable player in the global pharmaceutical market.

What is the history and background of the company Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries Ltd., established in 1950, is a leading global pharmaceutical company headquartered in Haifa Bay, Israel. With a rich history spanning over seven decades, Taro has evolved into a renowned manufacturer and marketer of high-quality prescription and over-the-counter pharmaceutical products. The company specializes in various therapeutic areas, including dermatology, cardiology, neurology, and more. Taro strives to provide patients worldwide with affordable and accessible medications to improve their quality of life. As a global player, Taro operates through subsidiaries, alliances, and distribution partnerships in multiple countries, demonstrating its commitment to global healthcare. Taro Pharmaceutical Industries Ltd. continuously explores innovative solutions and endeavors to meet the diverse healthcare needs of individuals worldwide.

Who are the main competitors of Taro Pharmaceutical Industries in the market?

The main competitors of Taro Pharmaceutical Industries Ltd in the market include global pharmaceutical companies such as Teva Pharmaceutical Industries Ltd, Mylan N.V., and Sun Pharmaceutical Industries Ltd. These companies compete with Taro Pharmaceutical Industries Ltd in the development, manufacturing, and marketing of generic and branded prescription pharmaceutical products. Their products may overlap in various therapeutic areas, creating competition in terms of cost, innovation, and market share.

In which industries is Taro Pharmaceutical Industries primarily active?

Taro Pharmaceutical Industries Ltd is primarily active in the pharmaceutical industry.

What is the business model of Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries Ltd is a leading company in the pharmaceutical industry. Their business model focuses on developing, manufacturing, and marketing high-quality prescription and over-the-counter medications. With a strong commitment to research and development, Taro aims to provide innovative solutions that meet the needs of patients around the world. By maintaining strict quality standards and adhering to regulatory guidelines, Taro ensures the safety and efficacy of their products. As a global company, Taro strives to expand its presence in various markets, offering a diverse portfolio of pharmaceutical products to maximize value for patients, healthcare professionals, and shareholders.

What is the P/E ratio of Taro Pharmaceutical Industries 2024?

The Taro Pharmaceutical Industries P/E ratio is 29.98.

What is the P/S ratio of Taro Pharmaceutical Industries 2024?

The Taro Pharmaceutical Industries P/S ratio is 2.57.

What is the Quality Investing of Taro Pharmaceutical Industries?

The Quality Investing for Taro Pharmaceutical Industries is 2/10.

What is the revenue of Taro Pharmaceutical Industries 2024?

The Taro Pharmaceutical Industries revenue is 629.18 M USD.

How high is the profit of Taro Pharmaceutical Industries 2024?

The Taro Pharmaceutical Industries profit is 53.87 M USD.

What is the business model of Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd is a global pharmaceutical company based in Israel with operational offices in North America, Europe, and Asia. The company specializes in the production and marketing of pharmaceutical products, serving both the prescription and OTC markets. The company is divided into three main business segments: generics, branded products, and OTC products. The generics segment is the largest area of the company, focusing on the production of generic drugs in various therapeutic categories such as dermatology, cardiology, gastroenterology, and oncology therapies. Taro has a wide range of branded products marketed in the USA, Canada, and other countries worldwide. The portfolio includes specific medications for the treatment of skin conditions, eye infections, pain and inflammation, cardiovascular diseases, and other disorders. Taro's OTC product range offers a variety of products for pain relief, cold, flu, allergies, heartburn, and other health-related complaints. The company operates a highly vertically integrated production chain that spans from research and development to production, marketing, and distribution of their products. Taro has a global presence and is committed to developing innovative, high-quality products and providing cost-effective solutions. Taro works closely with its global customers to ensure continuous product availability and achieve a strong market presence. The company is dedicated to delivering high-quality medications and adheres to strict quality standards throughout the manufacturing process. In addition to its business activities, Taro actively participates in charitable projects and encourages its employees to engage in social initiatives. The company values sustainable development and strives to counteract the environmental impacts of its business operations. Overall, Taro Pharmaceutical Industries Ltd's business model is focused on strong vertical integration and global presence. The company offers a wide range of generics, branded products, and OTC products aimed at meeting the medical needs of customers worldwide. Taro is committed to developing innovative products and providing high-quality solutions while actively engaging in social and sustainable projects.

What is the Taro Pharmaceutical Industries dividend?

Taro Pharmaceutical Industries pays a dividend of 0 USD distributed over payouts per year.

How often does Taro Pharmaceutical Industries pay dividends?

The dividend cannot currently be calculated for Taro Pharmaceutical Industries or the company does not pay out a dividend.

What is the Taro Pharmaceutical Industries ISIN?

The ISIN of Taro Pharmaceutical Industries is IL0010827181.

What is the Taro Pharmaceutical Industries WKN?

The WKN of Taro Pharmaceutical Industries is 897505.

What is the Taro Pharmaceutical Industries ticker?

The ticker of Taro Pharmaceutical Industries is TARO.

How much dividend does Taro Pharmaceutical Industries pay?

Over the past 12 months, Taro Pharmaceutical Industries paid a dividend of 12.86 USD . This corresponds to a dividend yield of about 29.93 %. For the coming 12 months, Taro Pharmaceutical Industries is expected to pay a dividend of 6.95 USD.

What is the dividend yield of Taro Pharmaceutical Industries?

The current dividend yield of Taro Pharmaceutical Industries is 29.93 %.

When does Taro Pharmaceutical Industries pay dividends?

Taro Pharmaceutical Industries pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries paid dividends every year for the past 1 years.

What is the dividend of Taro Pharmaceutical Industries?

For the upcoming 12 months, dividends amounting to 6.95 USD are expected. This corresponds to a dividend yield of 16.17 %.

In which sector is Taro Pharmaceutical Industries located?

Taro Pharmaceutical Industries is assigned to the 'Health' sector.

Wann musste ich die Aktien von Taro Pharmaceutical Industries kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Taro Pharmaceutical Industries from 12/28/2018 amounting to 12.86 USD, you needed to have the stock in your portfolio before the ex-date on 12/10/2018.

When did Taro Pharmaceutical Industries pay the last dividend?

The last dividend was paid out on 12/28/2018.

What was the dividend of Taro Pharmaceutical Industries in the year 2023?

In the year 2023, Taro Pharmaceutical Industries distributed 0 USD as dividends.

In which currency does Taro Pharmaceutical Industries pay out the dividend?

The dividends of Taro Pharmaceutical Industries are distributed in USD.

All fundamentals about Taro Pharmaceutical Industries

Our stock analysis for Taro Pharmaceutical Industries Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Taro Pharmaceutical Industries Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.